Market Cap 20.32M
Revenue (ttm) 0.00
Net Income (ttm) -34.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 78,000
Avg Vol 178,814
Day's Range N/A - N/A
Shares Out 8.61M
Stochastic %K 70%
Beta 1.29
Analysts Strong Sell
Price Target $19.50

Company Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 588 0256
Address:
448 NW Market Street, Suite 500, Seattle, United States
DHern924
DHern924 Aug. 10 at 12:22 AM
$ATOS hello hello have you not noticed the rest of the market? Wake the f up this week
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:34 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 5) But let us not deceive ourselves. This was no mere change of heart, no sudden enlightenment. It was, rather, the inevitable consequence of a game played in the shadows, where the pieces moved not by the hand of science alone, but by the invisible threads of power, profit, and the most human of all motivations: the desire to control the narrative. And so, as the dust settled and the new order took its place, one could not help but marvel at the exquisite irony of it all. For in the end, it was not the drug that had been held back, but the truth—and the truth, as ever, was the last guest to arrive at the banquet. Yet, in the balance of billions, what was a smaller sacrifice, if not a necessary one, to preserve the greater good—or so the righteous minds would have us believe?
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:33 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 4) And then, as if by some cruel jest of fate—or perhaps the quiet calculation of those who dispensed billions with the gravity of righteous minds—the earth itself seemed to shift. The doctor, that quiet architect of the drug’s science, ascended to the heights of the NIAID, and with his rise came a transformation as sudden as it was inexplicable. The landscape, once so stubbornly resistant, now bent as though in deference to a new wind. The tones softened, the objections melted, and the once-heretical notion of (z)-endoxifen’s superiority was met with nods of solemn approval. One might almost imagine the collective sigh of relief from those who had, for so long, held their breath, waiting for the moment when the tide would turn in their favor.
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:32 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 3) Ah, but here lay the rub: the interests that had so deftly guided tamoxifen’s ascent were not, as it happened, the same that would benefit from the rise of its more potent cousin. The development of (z)-endoxifen was a threat, a silent rebellion against the order of things, and rebellion, as any society matron might tell you, is a most unseemly business. The cost of its cultivation, the energy expended in its pursuit—these were sacrifices made at the altar of a future that certain parties had no intention of embracing. It was far simpler, after all, to let the status quo reign, to allow the familiar to remain unchallenged, than to risk the upheaval of a truth too bright to be contained.
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:31 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 2) For years, it had lingered in the wings, a silent understudy to tamoxifen, that grand dame of the pharmaceutical stage, whose profits flowed as steadily as the Thames and whose reputation was as untarnished as it was unassailable. Tamoxifen, with its air of established respectability, had long since secured its place at the table, its potency as unquestioned as the authority of a dowager in her drawing room. And yet, there it was—(z)-endoxifen—whispered about in corridors, its potential as undeniable as it was inconvenient. Why, one might ask, should a drug of such promise be relegated to the shadows, its light dimmed by the very hands that might have lifted it to prominence?
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:30 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 1) It was a truth universally acknowledged, though rarely spoken aloud, that the fate of a drug—no less than that of a man—was often determined not by its merit, but by the hands that cradled it, or, more precisely, the hands that withheld it. And so it was with (z)-endoxifen, that most enigmatic of compounds, whose very existence seemed to hang in a suspense as delicate as the pause of a violinist’s bow before the final, revealing note.
0 · Reply
Bunster
Bunster Aug. 9 at 12:13 PM
$ATOS so sad a great post. No replies and only one other like besides me
0 · Reply
The_Real_Heisenberg
The_Real_Heisenberg Aug. 9 at 10:29 AM
$ATOS Were about to explode.
2 · Reply
NotHopeJustFacts
NotHopeJustFacts Aug. 8 at 10:49 PM
$ATOS indeed, isn't that suspicious? How come such a genius like he claims he is, that find the best product to find cancer but he doesn't seem interested in making sure he gets approved?? Umm this is just POS and maybe a FAKE molecule just like the fake doctor he hired and that was a killer
0 · Reply
ShowMeThaMonay
ShowMeThaMonay Aug. 8 at 1:03 AM
$ATOS what are we thinking here? Anyone still buying or are we just waiting? Sad how this board and stock became pretty dead. Hopefully in the near future we will see Bunster posting “who are all these new posters?!” …meaning we get a pump. We will see 👍🏻
0 · Reply
Latest News on ATOS
Atossa Therapeutics reports Q2 EPS (95c) vs. (98c) last year

2026-08-07T12:52:02.000Z - 2 days ago

Atossa Therapeutics reports Q2 EPS (95c) vs. (98c) last year


Atossa Therapeutics Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 3 days ago

Atossa Therapeutics Quarterly report: Q2 2026


Atossa Therapeutics Earnings release: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 3 days ago

Atossa Therapeutics Earnings release: Q2 2026


Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel

2026-07-30T17:05:28.000Z - 10 days ago

Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel


Atossa Therapeutics initiated with a Buy at Rodman & Renshaw

2026-07-07T12:15:16.000Z - 4 weeks ago

Atossa Therapeutics initiated with a Buy at Rodman & Renshaw


Atossa Therapeutics announces $16.5M registered direct offering

2026-06-11T12:06:50.000Z - 2 months ago

Atossa Therapeutics announces $16.5M registered direct offering


Atossa Therapeutics Transcript: Status update

May 19, 2026, 4:00 PM EDT - 2 months ago

Atossa Therapeutics Transcript: Status update


Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year

2026-05-08T16:29:20.000Z - 3 months ago

Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year


Atossa Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

Atossa Therapeutics Quarterly report: Q1 2026


Atossa Therapeutics Earnings release: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

Atossa Therapeutics Earnings release: Q1 2026


Atossa Therapeutics Proxy statement: Proxy filing

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Atossa Therapeutics Proxy statement: Proxy filing


Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)

2026-03-25T21:40:26.000Z - 4 months ago

Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)


Atossa Therapeutics Earnings release: Q4 2025

Mar 25, 2026, 7:00 AM EDT - 4 months ago

Atossa Therapeutics Earnings release: Q4 2025


Atossa Therapeutics Annual report: Q4 2025

Mar 25, 2026, 7:00 AM EDT - 4 months ago

Atossa Therapeutics Annual report: Q4 2025


Atossa Therapeutics Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Proxy statement: Proxy filing


Atossa Therapeutics Slides: Corporate presentation

Feb 11, 2026, 6:00 AM EST - 6 months ago

Atossa Therapeutics Slides: Corporate presentation


Atossa Therapeutics Proxy statement: Proxy Filing

Dec 22, 2025, 7:00 AM EST - 8 months ago

Atossa Therapeutics Proxy statement: Proxy Filing


Atossa Therapeutics Proxy statement: Proxy Filing

Dec 12, 2025, 7:00 AM EST - 8 months ago

Atossa Therapeutics Proxy statement: Proxy Filing


Atossa Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 9 months ago

Atossa Therapeutics Earnings release: Q3 2025


Atossa Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 9 months ago

Atossa Therapeutics Quarterly report: Q3 2025


Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 15, 2025, 8:00 AM EDT - 10 months ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025


Atossa Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q2 2025


Atossa Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q2 2025


Atossa Therapeutics Transcript: Status Update

May 22, 2025, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Transcript: Status Update


Atossa Therapeutics Earnings release: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q1 2025


Atossa Therapeutics Quarterly report: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q1 2025


Atossa Therapeutics Proxy statement: Proxy Filing

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Proxy statement: Proxy Filing


Atossa Therapeutics Earnings Call Transcript: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings Call Transcript: Q4 2024


Atossa Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q4 2024


Atossa Therapeutics Annual report: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Annual report: Q4 2024


Atossa Therapeutics Slides: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Slides: Q4 2024


DHern924
DHern924 Aug. 10 at 12:22 AM
$ATOS hello hello have you not noticed the rest of the market? Wake the f up this week
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:34 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 5) But let us not deceive ourselves. This was no mere change of heart, no sudden enlightenment. It was, rather, the inevitable consequence of a game played in the shadows, where the pieces moved not by the hand of science alone, but by the invisible threads of power, profit, and the most human of all motivations: the desire to control the narrative. And so, as the dust settled and the new order took its place, one could not help but marvel at the exquisite irony of it all. For in the end, it was not the drug that had been held back, but the truth—and the truth, as ever, was the last guest to arrive at the banquet. Yet, in the balance of billions, what was a smaller sacrifice, if not a necessary one, to preserve the greater good—or so the righteous minds would have us believe?
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:33 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 4) And then, as if by some cruel jest of fate—or perhaps the quiet calculation of those who dispensed billions with the gravity of righteous minds—the earth itself seemed to shift. The doctor, that quiet architect of the drug’s science, ascended to the heights of the NIAID, and with his rise came a transformation as sudden as it was inexplicable. The landscape, once so stubbornly resistant, now bent as though in deference to a new wind. The tones softened, the objections melted, and the once-heretical notion of (z)-endoxifen’s superiority was met with nods of solemn approval. One might almost imagine the collective sigh of relief from those who had, for so long, held their breath, waiting for the moment when the tide would turn in their favor.
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:32 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 3) Ah, but here lay the rub: the interests that had so deftly guided tamoxifen’s ascent were not, as it happened, the same that would benefit from the rise of its more potent cousin. The development of (z)-endoxifen was a threat, a silent rebellion against the order of things, and rebellion, as any society matron might tell you, is a most unseemly business. The cost of its cultivation, the energy expended in its pursuit—these were sacrifices made at the altar of a future that certain parties had no intention of embracing. It was far simpler, after all, to let the status quo reign, to allow the familiar to remain unchallenged, than to risk the upheaval of a truth too bright to be contained.
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:31 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 2) For years, it had lingered in the wings, a silent understudy to tamoxifen, that grand dame of the pharmaceutical stage, whose profits flowed as steadily as the Thames and whose reputation was as untarnished as it was unassailable. Tamoxifen, with its air of established respectability, had long since secured its place at the table, its potency as unquestioned as the authority of a dowager in her drawing room. And yet, there it was—(z)-endoxifen—whispered about in corridors, its potential as undeniable as it was inconvenient. Why, one might ask, should a drug of such promise be relegated to the shadows, its light dimmed by the very hands that might have lifted it to prominence?
0 · Reply
Michaeljin_101
Michaeljin_101 Aug. 9 at 6:30 PM
$ATOS The Curious Case of (z)-Endoxifen: A Study in Shadows (Part 1) It was a truth universally acknowledged, though rarely spoken aloud, that the fate of a drug—no less than that of a man—was often determined not by its merit, but by the hands that cradled it, or, more precisely, the hands that withheld it. And so it was with (z)-endoxifen, that most enigmatic of compounds, whose very existence seemed to hang in a suspense as delicate as the pause of a violinist’s bow before the final, revealing note.
0 · Reply
Bunster
Bunster Aug. 9 at 12:13 PM
$ATOS so sad a great post. No replies and only one other like besides me
0 · Reply
The_Real_Heisenberg
The_Real_Heisenberg Aug. 9 at 10:29 AM
$ATOS Were about to explode.
2 · Reply
NotHopeJustFacts
NotHopeJustFacts Aug. 8 at 10:49 PM
$ATOS indeed, isn't that suspicious? How come such a genius like he claims he is, that find the best product to find cancer but he doesn't seem interested in making sure he gets approved?? Umm this is just POS and maybe a FAKE molecule just like the fake doctor he hired and that was a killer
0 · Reply
ShowMeThaMonay
ShowMeThaMonay Aug. 8 at 1:03 AM
$ATOS what are we thinking here? Anyone still buying or are we just waiting? Sad how this board and stock became pretty dead. Hopefully in the near future we will see Bunster posting “who are all these new posters?!” …meaning we get a pump. We will see 👍🏻
0 · Reply
TheChangedBear
TheChangedBear Aug. 7 at 11:34 PM
$ATOS Seems your the only one with wet undies, Dumpster.
0 · Reply
Bunster
Bunster Aug. 7 at 10:46 PM
$ATOS BREAKING PER FINTEL BLACKROCK REPORTED TODAY ON 13F OWNING164358 SHARES UP 23.42PCT SINCE LAST TIME.BULLS DONT GET EXCITED . OVER THE YEARS THEY BUY THEY SELL THEY SELL THEY BUY. . KIND OF LIKE A TUTES VERSION OF OUR IN AND OUT// prime
1 · Reply
Bunster
Bunster Aug. 7 at 10:32 PM
$ATOS primes week in review.. august 7 2026 pps 2.36 MVP outdid himself er out When i said dont be surprised if halted for news pending i meant the quay news dropping during market hours.just a thought.
1 · Reply
Kittyc803
Kittyc803 Aug. 7 at 4:04 PM
$ATOS ER out . We coming to a head . Give it until Oct , Nov . Then we know 😀 LFG 🗣️
0 · Reply
RichardDangler
RichardDangler Aug. 7 at 4:04 PM
$ATOS found the section on cash a bit further down. Looks like they have about $26,000,000 in cash at the moment. They spent about $4,600,000 per quarter most recently, or $1,150,000 per month. That leaves about 22 months of working capital assuming warrants aren’t excercised down the road. That puts us at 06/2028, however they would likely try and find an avenue for more cash to end the year 2027, or early 2028. That’s a key target if you’re an investor looking to exit, or worried about new dilution. Still looking to get out at $5.
0 · Reply
samirsss
samirsss Aug. 7 at 4:01 PM
$ATOS Evangeline trial enrollment is full on June 30th so any day now we should get the results from that. This is fantastic news
5 · Reply
RichardDangler
RichardDangler Aug. 7 at 4:01 PM
0 · Reply
Cheffinance
Cheffinance Aug. 7 at 3:53 PM
$ATOS cash until 2028, read
0 · Reply
RichardDangler
RichardDangler Aug. 7 at 3:52 PM
$ATOS I see they no longer mention their current cash positions in financial updates.. based on the operating expenses of $8+ million, and only getting $4.5 million from the direct offering, I’m assuming they don’t have much working capital left to continue on? They aren’t sitting on much cash at all to keep going without further dilution/funding. Really wonder what the plan is there. CFO needs to be fired, quay needs the boot.
0 · Reply
Cheffinance
Cheffinance Aug. 7 at 3:16 PM
$ATOS bastards
0 · Reply
NOYES
NOYES Aug. 7 at 2:42 PM
$ATOS nothing exciting yet..
0 · Reply
MrMojoRising1
MrMojoRising1 Aug. 7 at 2:32 PM
$ATOS every time this gets a little momentum these assholes (management) seem to knock it back down. How about some positive news for once WTF.....
1 · Reply